Key Market Insights

• Presently, more than 25 therapeutics and vaccines are either marketed or under preclinical / clinical development for the treatment and prevention of monkeypox disease
• Majority of the pipeline candidates are biologics, which are available in liquid dosage form; over 50% of the products are designed for oral administration
• More than 165 diagnostic kits are currently available in the market for the detection of monkeypox virus; these kits utilize various detection methods for monkeypox diagnosis
• Over 75% of the monkeypox diagnostic kits use polymerase chain reaction (PCR) as the detection method; more than 35% of such kits can detect the virus in less than 30 minutes
• In pursuit of gaining a competitive edge, monkeypox diagnostic kit providers are presently undertaking initiatives to expand their existing capabilities and augment respective product portfolios
• The growing interest in this domain is evident from the rise in partnership activity; in fact, the maximum number of collaborations related to monkeypox therapeutics and vaccines were inked in 2022
• Grants worth over USD 250 million, disbursed across 270+ instances, have been awarded for research related to monkeypox; nearly 80% of these grants extend a support period of up to 10 years
• The recent rise in number of scientific articles being published in this domain reflects the growing efforts of industry and academic stakeholders
• Considering that the market for Mpox therapeutics / vaccines and diagnostics kits is currently very niche, featuring the presence of only a few players, the threat of new entrants is significant
• The monkeypox therapeutics / vaccines market’s evolution is likely to be driven by the rising need for novel drug candidates; the market is anticipated to grow at a healthy pace in the foreseen future
• The overall opportunity within monkeypox diagnostic kits market is anticipated to be well distributed across various types of kits, end users and key geographical regions

Table of Contents

1. EXECUTIVE SUMMARY
2. INTRODUCTION
   2.1. An Overview of Monkeypox
   2.2. Signs and Symptoms
   2.3. History of Disease Outbreaks
   2.4. Disease Transmission
   2.5. Disease Diagnosis
   2.6. Prevention and Treatment
   2.6.1. Prevention Measures
   2.6.2. Available Therapeutics and Vaccines
   2.7. Future Perspectives
3. MARKET LANDSCAPE: MONKEYPOX THERAPEUTICS AND VACCINES
   3.1. Monkeypox Therapeutics and Vaccines: Overall Market Landscape
   3.1.1. Analysis by Phase of Development
   3.1.2. Analysis by Type of Product
   3.1.3. Analysis by Phase of Development and Type of Product
   3.1.4. Analysis by Type of Molecule
   3.1.5. Analysis by Type of Dosage Form
   3.1.6. Analysis by Route of Administration

3.2. Monkeypox Therapeutics and Vaccines: Developer Landscape
3.2.1. Analysis by Year of Establishment
3.2.2. Analysis by Type of Player
3.2.3. Analysis by Geography (Region-wise)
3.2.4. Analysis by Company Size and Geography (Region-wise)
3.2.5. Leading Developers: Analysis by Number of Therapeutics / Vaccines

4. MARKET LANDSCAPE: MONKEYPOX DIAGNOSTIC KITS
   4.1. Monkeypox Diagnostic Kits: Overall Market Landscape
   4.1.1. Analysis by Type of Sample
   4.1.2. Analysis by Type of Kit Component
   4.1.3. Analysis by Clade of Virus Detected
   4.1.4. Analysis by Detection Method
   4.1.5. Analysis by Application Area
   4.1.6. Analysis by Type of Kit
   4.1.7. Analysis by Quantity of Sample
   4.1.8. Analysis by Turnaround Time
   4.1.9 Analysis by Limit of Detection
   4.1.10. Analysis by Number of Tests per Kit
   4.1.11. Analysis by Shelf Life
   4.1.12. Analysis by Storage Temperature

4.2 Monkeypox Diagnostic Kits: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Type of Developer
4.2.6. Key Developers: Analysis by Number of Diagnostic Kits Developed

5. MONKEYPOX DIAGNOSTIC KITS: PRODUCT COMPETITIVENESS ANALYSIS
   5.1. Methodology
   5.2. Product Competitiveness Analysis: Monkeypox Diagnostic Kits
6. COMPANY PROFILES: MONKEYPOX THERAPEUTICS AND VACCINES DEVELOPERS
   6.1. Bavarian Nordic
   6.1.1. Company Overview
   6.1.2. Monkeypox Therapeutics / Vaccines Portfolio
   6.1.3. Recent Developments and Future Outlook

6.2. Emergent BioSolutions
6.2.1. Company Overview
6.2.2. Monkeypox Therapeutics / Vaccines Portfolio
6.2.3. Recent Developments and Future Outlook

7. COMPANY PROFILES: MONKEYPOX DIAGNOSTIC KITS DEVELOPERS
   7.1. ACON Laboratories
   7.1.1. Company Overview
   7.1.2. Monkeypox Diagnostic Kits Portfolio

7.2. altona Diagnostics

7.3. DNA Software

7.4. Elabscience

7.5. Goldsite Diagnostics

7.6. Hangzhou Testsea Biotechnology

7.7. Jiangsu Bioperfectus Technologies

7.8. Lansion Biotechnology

8. PARTNERSHIPS AND COLLABORATIONS
   8.1. Monkeypox Therapeutics / Vaccines and Diagnostic Kits: Partnerships and Collaborations
   8.1.1. Analysis by Year of Partnership
   8.1.2. Analysis by Type of Partnership
   8.1.3. Analysis by Year and Type of Partnership
   8.1.4. Analysis by Focus Area
   8.1.5. Analysis by Type of Partner
   8.1.6. Most Active Players: Analysis by Number of Partnerships
   8.1.7. Analysis by Local and International Agreements
   8.1.8. Analysis by Intercontinental and Intracontinental Agreements
9. GRANTS ANALYSIS
   9.1. Scope and Methodology
   9.2. Key Parameters
   9.3. Monkeypox Therapeutics / Vaccines and Diagnostic Kits: Grants Analysis
   9.3.1. Analysis by Year of Grant Awarded
   9.3.2. Analysis by Support Period
   9.3.3. Analysis by Amount Awarded
   9.3.4. Analysis by Leading Funding Institute Centre
   9.3.5. Analysis by Type of Grant
   9.3.6. Analysis by Activity Code
   9.3.7. Analysis by Study Section Involved
   9.3.8. Analysis by Purpose of Grant
   9.3.9. Prominent Program Officers: Analysis by Number of Grants
   9.3.10. Popular Recipient Organizations: Analysis by Number of Grants and Amount Awarded
   9.3.11. Most Popular Departments: Analysis by Number of Grants
   9.3.12. Analysis by Location of Recipient
10. PUBLICATION ANALYSIS
    10.1. Methodology and Parameters
    10.2. Monkeypox Therapeutics / Vaccines and Diagnostic Kits: Publication Analysis
    10.2.1. Analysis by Year of Publication
    10.2.2. Analysis by Type of Publication
    10.2.3. Most Popular Journals: Analysis by Number of Publications
    10.2.4. Most Popular Journals: Analysis by Journal Impact Factor
    10.2.5. Popular Keywords: Analysis by Key Focus Areas
    10.2.6. Most Active Publishers: Analysis by Number of Publications
    10.2.7. Most Popular Affiliations: Analysis by Number of Publications
    10.2.8. Analysis by Geography
11. PORTER’S FIVE FORCES ANALYSIS
    11.1. Chapter Overview
    11.2. Methodology and Key Parameters
    11.3. Porter’s Five Forces
    11.3.1. Threat of New Entrants
    11.3.2. Bargaining Power of End Users
    11.3.3. Bargaining Power of Drug Developers
    11.3.4. Threat of Substitute Products
    11.3.5. Rivalry Among Existing Competitors
12. MARKET FORECAST: MONKEYPOX THERAPEUTICS AND VACCINES
    12.1. Chapter Overview
    12.2. Key Assumptions and Forecast Methodology
    12.3. Global Monkeypox Therapeutics and Vaccines Market, 2023-2035
    12.3.1. Monkeypox Therapeutics and Vaccines Market: Analysis by Type of Product, 2023 and 2035
    12.3.1.1. Monkeypox Therapeutics Market, 2023-2035
    12.3.1.2. Monkeypox Vaccines Market, 2023-2035

12.3.2. Monkeypox Therapeutics and Vaccines Market: Analysis by Drug Developers, 2023 and 2035
12.3.2.1. Monkeypox Therapeutics and Vaccines Market for Bavarian Nordic, 2023-2035
12.3.2.2. Monkeypox Therapeutics and Vaccines Market for Emergent BioSolutions, 2023-2035
12.3.2.3. Monkeypox Therapeutics and Vaccines Market for KM Biologics, 2023-2035
12.3.2.4. Monkeypox Therapeutics and Vaccines Market for SIGA Technologies, 2023-2035

12.3.3. Monkeypox Therapeutics and Vaccines Market: Analysis by Drug Candidates, 2023 and 2035
12.3.3.1. IMVANEX® / JYNNEOS® / IMVAMUNER® (Bavarian Nordic): Sales Forecast, 2023-2035
12.3.3.2. ACAM2000 (Emergent BioSolutions): Sales Forecast, 2023-2035
12.3.3.3. VIGIV / CNJ-016 (Emergent BioSolutions): Sales Forecast, 2023-2035
12.3.3.4. LC16KMB (KM Biologics): Sales Forecast: Sales Forecast, 2023-2035
12.3.3.5. Tecovirimat / ST-246 / TPOXX (SIGA Technologies): Sales Forecast, 2023-2035

12.3.4. Monkeypox Therapeutics and Vaccines Market: Analysis by Geography, 2023 and 2035
12.3.4.1. Monkeypox Therapeutics and Vaccines Market in North America, 2023-2035
12.3.4.1.1. Monkeypox Therapeutics and Vaccines Market in the US, 2023-2035
12.3.4.1.2. Monkeypox Therapeutics and Vaccines Market in Canada, 2023-2035

12.3.4.2. Monkeypox Therapeutics and Vaccines Market in Europe, 2023-2035
12.3.4.2.1. Monkeypox Therapeutics and Vaccines Market in the UK, 2023-2035
12.3.4.2.2. Monkeypox Therapeutics and Vaccines Market in France, 2023-2035
12.3.4.2.3. Monkeypox Therapeutics and Vaccines Market in Germany, 2023-2035
12.3.4.2.4. Monkeypox Therapeutics and Vaccines Market in Spain, 2023-2035
12.3.4.2.5. Monkeypox Therapeutics and Vaccines Market in Italy, 2023-2035
13.3.4.2.6. Monkeypox Therapeutics and Vaccines Market in Rest of Europe, 2023-2035

12.3.4.3. Monkeypox Therapeutics and Vaccines Market in Asia Pacific, 2023-2035
12.3.4.3.1. Monkeypox Therapeutics and Vaccines Market in Japan, 2023-2035
12.3.4.3.2. Monkeypox Therapeutics and Vaccines Market in Australia, 2023-2035

13. MARKET FORECAST: MONKEYPOX DIAGNOSTIC KITS
    13.1. Chapter Overview
    13.2. Key Assumptions and Forecast Methodology
    13.3. Global Monkeypox Diagnostic Kits Market, 2023-2035
    13.3.1. Monkeypox Diagnostic Kits Market: Analysis by Type of Kit, 2023 and 2035
    13.3.1.1. Monkeypox Polymerase Chain Reaction (PCR) Detection Kits Market, 2023-2035
    13.3.1.2. Monkeypox Antigen Detection Kits Market, 2023-2035
    13.3.1.3 Monkeypox Antibody Detection Kits Market, 2023-2035

13.3.2. Monkeypox Diagnostic Kits Market: Analysis by Type of End User, 2023 and 2035
13.3.2.1. Monkeypox Diagnostic Kits Market for Hospitals and Clinics, 2023-2035
13.3.2.2. Monkeypox Diagnostic Kits Market for Diagnostic Laboratories, 2023-2035
13.3.2.3. Monkeypox Diagnostic Kits Market for Other End Users, 2023-2035

13.3.3. Monkeypox Diagnostic Kits Market: Analysis by Geography, 2023 and 2035
13.3.3.1. Monkeypox Diagnostic Kits Market in North America, 2023-2035
13.3.3.1.1. Monkeypox Diagnostic Kits Market in the US, 2023-2035
13.3.3.1.2. Monkeypox Diagnostic Kits Market in Canada, 2023-2035

13.3.3.2. Monkeypox Diagnostic Kits Market in Europe, 2023-2035
13.3.3.2.1. Monkeypox Diagnostic Kits Market in the UK, 2023-2035
13.3.3.2.2. Monkeypox Diagnostic Kits in France, 2023-2035
13.3.3.2.3. Monkeypox Diagnostic Kits Market in Germany, 2023-2035
13.3.3.2.4. Monkeypox Diagnostic Kits Market in Spain, 2023-2035
13.3.3.2.5. Monkeypox Diagnostic Kits Market in Italy, 2023-2035
13.3.3.2.6. Monkeypox Diagnostic Kits Market in Rest of Europe, 2023-2035

13.3.3.3. Monkeypox Diagnostic Kits Market in Asia Pacific, 2023-2035
13.3.3.3.1. Monkeypox Diagnostic Kits Market in Japan, 2023-2035
13.3.3.3.2. Monkeypox Diagnostic Kits Market in Australia, 2023-2035

14. EXECUTIVE INSIGHTS
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

To view more details on this report, click on the link

https://www.rootsanalysis.com/reports/monkeypox-treatment-market.html

You may also be interested in the following titles:

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415

Ben.johnson@rootsanalysis.com